DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Update

DBV Technologies S.A. (NASDAQ:DBVTGet Free Report) saw a large increase in short interest in July. As of July 31st, there was short interest totalling 307,100 shares, an increase of 6.3% from the July 15th total of 288,800 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average trading volume of 94,100 shares, the days-to-cover ratio is presently 3.3 days.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on DBVT shares. StockNews.com began coverage on shares of DBV Technologies in a research note on Sunday. They set a “hold” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of DBV Technologies in a research report on Thursday, August 1st. Finally, JMP Securities lifted their target price on DBV Technologies from $4.00 to $5.00 and gave the company a “market outperform” rating in a report on Wednesday, July 31st.

View Our Latest Research Report on DBVT

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVTFree Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 50,986 shares of the company’s stock, valued at approximately $49,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Price Performance

Shares of DBVT traded down $0.01 during midday trading on Friday, reaching $0.93. The stock had a trading volume of 5,736 shares, compared to its average volume of 51,975. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $3.70. The company has a market cap of $89.98 million, a price-to-earnings ratio of -1.11 and a beta of 0.68. The company’s fifty day simple moving average is $0.91 and its two-hundred day simple moving average is $1.26.

DBV Technologies (NASDAQ:DBVTGet Free Report) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The company had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. During the same quarter in the prior year, the company earned ($0.26) earnings per share. On average, sell-side analysts forecast that DBV Technologies will post -1.22 earnings per share for the current year.

About DBV Technologies

(Get Free Report)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

Read More

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.